Trial Profile
Clinical Trials Insight: 700050418
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs KP 106 (Primary) ; Lisdexamfetamine
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Pharmacokinetics
- 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
- 12 Jan 2010 Positive results reported in a KemPharm media release.
- 12 Jan 2010 Status changed from recruiting to completed as reported in a KemPharm media release.